So far, Novo Nordisk’s focus on diabetes has appeared to pay off – it’s riding high with a leading insulin franchise in an expanding market. Novo has shown in insulin that it can beat the big guys. But hte company should exploit its biopharma skills more aggressively and more broadly to remain on its current growth curve.
